Corpus overview


Overview

MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 1 - 3 records in total 3
    records per page




    Follow-up study on serum cholesterol profiles in recovered COVID-19 MESHD patients

    Authors: Guiling Li; Li Du; Xiaoling Cao; Xiuqi Wei; Yao Jiang; Yuqi Lin; Vi Nguyen; Wenbin Tan; Hui Wang

    doi:10.1101/2020.12.08.20245977 Date: 2020-12-11 Source: medRxiv

    COVID-19 MESHD patients develop hypolipidemia MESHD. However, it is unknown whether lipid levels have improved in recovered patients. In this study, a 3-6 month follow-up study was performed to examine serum levels of laboratory values in 107 discharged COVID-19 MESHD patients (mild = 59; severe/critical = 48; diagnoses on admission). 61 patients had a revisit chest CT scan. A Wilcoxon signed-rank test was used to analyze changes in laboratory values. LDL-c HGNC and HDL-c levels were significantly higher at follow-up than at admission in severe/critical cases (p < 0.05). LDL-c HGNC levels were significantly higher at follow-up than at admission in mild cases (p < 0.05). With adjustment of the factor of traditional Chinese medicine, LDL-c HGNC and HDL-c levels were significantly improved at follow-up than at admission in severe/critical cases (p < 0.05). Increases in HDL-c significantly correlated with increases in numbers of white blood cells (p<0.001) and decreases in levels of C-reactive protein HGNC (p < 0.05) during patients recovery. Residue lesions were observed in CT images in 69% (42 of 61) of follow-up patients. We concluded that improvements of LDL-c HGNC, HDL-c and incomplete absorption of lung lesions MESHD were observed at follow-up for recovered patients, indicating that a long-term recovery process could be required.

    Follow-up study on serum cholesterol profiles in recovered COVID-19 MESHD patients

    Authors: Wenbin Tan; Guiling Li; Li Du; Xiuqi Wei; Xiaoling Cao; Jiang Yao; Yuqi Lin; Vi Nguyen; Hui Wang

    doi:10.21203/rs.3.rs-118803/v1 Date: 2020-11-30 Source: ResearchSquare

    Background: COVID-19 MESHD patients develop hypolipidemia MESHD. However, it is unknown whether lipid levels have improved in recovered patients.Objective: In this follow-up study, we evaluated serum lipidemia MESHD and other physiopathological laboratory values in recovered patients.Methods: A 3–6 month follow-up study was performed between June 15 and September 3, 2020, to examine serum levels of laboratory values in 107 discharged COVID-19 MESHD patients (mild = 59; severe/critical = 48; diagnoses on admission). 61 patients had a revisit chest CT scan. A Wilcoxon signed-rank test was used to analyze changes in laboratory values at admission and follow-up.Results: LDL-c HGNC and HDL-c levels were significantly higher at follow-up than at admission in severe/critical cases (p < 0.05). LDL-c HGNC levels were significantly higher at follow-up than at admission in mild cases (p < 0.05). With adjustment of the factor of traditional Chinese medicine, LDL-c HGNC and HDL-c levels were significantly improved at follow-up than at admission in severe/critical cases (p < 0.05). Coagulation and liver laboratory values were significantly lower at follow-up than at admission for patients (p < 0.05). Increases in HDL-c significantly correlated with increases in numbers of white blood cells (p<0.001) and decreases in levels of C-reactive protein HGNC (p < 0.05) during patients’ recovery. Residue lesions were observed in CT images in 69% (42 of 61) of follow-up patients.Conclusions: Improvements of LDL-c HGNC, HDL-c and incomplete absorption of lung lesions MESHD were observed at 3–6 month follow-up for recovered patients, indicating that a long-term recovery process could be required. 

    Low-density lipoprotein cholesterol levels are associated with poor clinical outcomes in COVID-19 MESHD

    Authors: Alvaro Aparisi; Carolina Iglesias-Echeverria; Cristina Ybarra-Falcon; Ivan Cusacovich; Aitor Uribarri; Mario Garcia-Gomez; Raquel Ladron; Raul Fuertes; Jordi Candela; Williams Hinojosa; Carlos Duenas; Roberto Gonzalez; Leonor Nogales-Martin; Dolores Calvo; Manuel Carrasco-Moraleja; J. Alberto San Roman; Ignacio J Amat-Santos; David Andaluz Ojeda

    doi:10.1101/2020.10.06.20207092 Date: 2020-10-08 Source: medRxiv

    Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the sole causative agent of coronavirus infectious disease MESHD-19 ( COVID-19 MESHD). Methods: We performed a retrospective single-center study of consecutively admitted patients between March 1 HGNCst and May 15th, 2020, with a definitive diagnosis of SARS-CoV-2 infection MESHD. The primary endpoint was to evaluate the association of lipid markers with 30-days all-cause mortality in COVID-19 MESHD. Results: A total of 654 patients were enrolled, with an estimated 30-day mortality of 22.8% (149 patients). Non-survivors had lower total cholesterol (TC) and low-density lipoprotein cholesterol ( LDL-c HGNC) levels during the entire course of the disease with complete resolution among survivors. Both showed a significant inverse correlation with inflammatory markers and a positive correlation with lymphocyte count. In a multivariate analysis, LDL-c HGNC < 69 mg/dl (hazard ratio [HR] 1.94; 95% confidence interval [CI] 1.14-3.31), C-reactive protein HGNC > 88 mg/dl (HR 2.44; 95% CI, 1.41-4.23) and lymphopenia MESHD < 1000 cells/ml (HR 2.68; 95% CI, 1.91-3.78) at admission were independently associated with 30-day mortality. This association was maintained 7 days after admission. Conclusion: Hypolipidemia in SARS-CoV-2 infection MESHD SARS-CoV-2 infection MESHD may be secondary to an immune-inflammatory response, with complete recovery in survivors. Low LDL-c HGNC serum levels are independently associated with higher 30-day mortality in COVID-19 MESHD patients.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.